Posts

Showing posts with the label CDKL5 Deficiency Disorder

CDKL5 Deficiency Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 CDKL5 deficiency disorder, also known as CDD, is a rare genetic condition causing seizures, developmental delay, and severe intellectual disability, often beginning within months of birth and proving resistant to medication. This X-linked dominant disorder shares similarities with classic Rett syndrome, such as developmental issues and loss of language skills, but is distinguished by the early onset of recurrent seizures. CDD is caused by mutations affecting the CDKL5 protein, with some altering a critical amino acid for its kinase function and others producing nonfunctional variants. Currently, there are no approved treatments for CDD apart from Anti-Epileptic Drugs (AEDs) to manage seizures. ·        This disorder affects approximately 1 in 40,000 to 60,000 newborns and is one of the more prevalent genetic epilepsy forms.   Thelansis’s “CDKL5 Deficiency Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Repo...

CDKL5 Deficiency Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 CDKL5 deficiency disorder is a genetic disorder that causes seizures, developmental delay, and severe intellectual disability. Seizures typically begin within a few months after birth and are difficult to control with medications. Most children have 1 to 5 seizures every day. It is an X-linked dominant disorder. This disorder includes many features of classic Rett syndrome (including developmental problems, loss of language skills, and repeated hand wringing or hand washing movements) but also causes recurrent seizures beginning in infancy. ·        Some CDKL5 mutations change a single protein building block (amino acid) in a region of the CDKL5 protein that is critical for its kinase function. Other mutations lead to the production of an abnormally short, nonfunctional version of the protein. ·        There are currently no approved drugs to treat CDKL5 Deficiency, save for Anti-Epileptic Drugs (AEDs) to treat epilep...

CDKL5 Deficiency Disorder – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Image
CDKL5 deficiency disorder is a genetic disorder that causes seizures, developmental delay, and severe intellectual disability. Seizures typically begin within a few months after birth and are difficult to control with medications. Most children have 1 to 5 seizures every day. It is an X-linked dominant disorder ·        This disorder includes many of the features of classic Rett syndrome (including developmental problems, loss of language skills, and repeated hand wringing or hand washing movements), but also causes recurrent seizures beginning in infancy ·        Some CDKL5 mutations change a single protein building block (amino acid) in a region of the CDKL5 protein that is critical for its kinase function. Other mutations lead to the production of an abnormally short, nonfunctional version of the protein ·        There are currently no approved drugs to treat CDKL5 Deficiency, save for Anti-Epil...